Innocan Pharma Corp. buy Frank04
Start price
18.09.23
/
70%
€0.26
Target price
18.09.24
€1.00
Performance (%)
-37.77%
End price
19.09.24
€0.16
Summary
This prediction ended on 19.09.24 with a price of €0.16. The BUY prediction by Frank04 for Innocan Pharma Corp. performed very badly with a performance of -37.77%. Frank04 has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Innocan Pharma Corp. | - | - | - |
| iShares Core DAX® | 0.936% | 1.535% | 21.949% |
| iShares Nasdaq 100 | 3.064% | 1.968% | 29.275% |
| iShares Nikkei 225® | 1.898% | -0.295% | 14.740% |
| iShares S&P 500 | 1.653% | 2.318% | 27.064% |
According to Frank04 what are the pros and cons of Innocan Pharma Corp. for the foreseeable future?
Pros
Differentiated customer and product portfolio
Leading role in innovation
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Good rating
Very capable Management
Some uniques
Cons
Higher risks for its business
Comments by Frank04 for this prediction
In the thread Innocan Pharma Corp. diskutieren
Buy Innocan Pharma Corp.
In the thread Trading Innocan Pharma Corp.
Die von Frank04 gewählte maximale Laufzeit wurde überschritten